COPAXONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COPAXONE (COPAXONE).
Glatiramer acetate is a mixture of synthetic polypeptides that modulates immune responses by inducing anti-inflammatory T-cells and altering antigen-presenting cell function, reducing demyelination in multiple sclerosis.
| Metabolism | Glatiramer acetate is degraded locally by proteases; systemic metabolism is minimal. |
| Excretion | Glatiramer acetate is extensively metabolized locally at the injection site and in regional tissues. Unchanged drug is not detected in urine or feces. Less than 1% of a dose is excreted renally as low molecular weight fragments. Biliary/fecal excretion is negligible. |
| Half-life | The terminal elimination half-life of glatiramer acetate is complex due to depot release from injection site and metabolic degradation. After subcutaneous administration, the estimated terminal half-life of intact drug or its active metabolites is approximately 1-2 hours, but clinical activity relates more to immunomodulatory effects persisting beyond plasma clearance. |
| Protein binding | Glatiramer acetate is a mixture of polypeptides; protein binding data not well defined. It is not significantly bound to plasma proteins (<10%) due to its highly charged, hydrophilic nature. |
| Volume of Distribution | Volume of distribution not established due to rapid local metabolism. Given its large molecular weight and charged nature, distribution is primarily limited to extracellular fluid and injection site depot; a typical Vd for macromolecules is approximately 0.1-0.3 L/kg. |
| Bioavailability | Subcutaneous bioavailability is approximately 100% (administered subcutaneously). Oral absorption is negligible (<1%) due to gastrointestinal degradation. No other routes are clinically relevant. |
| Onset of Action | Clinical effect onset is delayed. Immunomodulatory changes (e.g., cytokine shifts) begin within 1-3 months of daily subcutaneous dosing. Clinically meaningful reduction in relapse rate in relapsing-remitting multiple sclerosis is typically observed after 3-6 months of continuous therapy. |
| Duration of Action | The duration of immunomodulatory action persists for days to weeks after cessation of dosing due to induced immune tolerance. Clinically, the relapse rate reduction is maintained with continuous daily administration. Discontinuation leads to gradual reversal of effect over months. |
20 mg subcutaneously once daily; alternatively, 40 mg subcutaneously three times per week at least 48 hours apart.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment. Not studied in severe renal impairment (GFR <15 mL/min). |
| Liver impairment | No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use with caution due to potential for increased sensitivity and comorbidities. Clinical studies did not include sufficient numbers of patients aged 65 and over. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for COPAXONE (COPAXONE).
| Breastfeeding | Unknown if glatiramer acetate is excreted in human milk. M/P ratio not determined. Risk to nursing infant cannot be ruled out. Use with caution, weighing benefit to mother versus potential risk to infant. |
| Teratogenic Risk | FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. In humans, limited data; no increased risk of major birth defects observed in postmarketing reports. Trimester-specific risks are not established; discontinue only if clearly necessary. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to glatiramer acetate or mannitol"]
| Precautions | ["Immediate post-injection reaction (e.g., flushing, chest pain, palpitations, anxiety, dyspnea) occurring within minutes of injection","Lipoatrophy and skin necrosis at injection sites","Potential for immune-mediated reactions (e.g., anaphylaxis, angioedema)","Use with caution in patients with pre-existing cardiac disease"] |
Loading safety data…
| No specific maternal or fetal monitoring required beyond routine prenatal care. Monitor for hypersensitivity reactions or injection site reactions. Fetal growth and well-being as per standard obstetric guidelines. |
| Fertility Effects | No adverse effects on fertility observed in animal studies. No human data on fertility impact. Considered unlikely to affect fertility in women or men. |